World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
40048
World Ranking
6039
National Ranking
3229

Overview

Richard Pazdur is affiliated with the US Food and Drug Administration in the United States. Their research is primarily focused on medicine, with a strong emphasis on oncology and related subfields.

Their work spans multiple subfields including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Economics and Econometrics
  • Surgery

Richard Pazdur's research covers a range of topics, concentrating on:

  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Advanced Breast Cancer Therapies
  • Health Systems, Economic Evaluations, Quality of Life
  • Economic and Financial Impacts of Cancer
  • Lung Cancer Treatments and Mutations
  • Statistical Methods in Clinical Trials

Their publication record includes recent papers such as:

  • FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors, 2021, Clinical Cancer Research
  • FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC, 2021, Clinical Cancer Research
  • The Drug-Dosing Conundrum in Oncology - When Less Is More, 2021, New England Journal of Medicine
  • Trends in the approval of cancer therapies by the FDA in the twenty-first century, 2023, Nature Reviews Drug Discovery
  • FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer, 2022, Clinical Cancer Research

Richard Pazdur frequently collaborates with several coauthors, including:

  • Julia A. Beaver
  • Paul G. Kluetz
  • Marc R. Theoret
  • Shenghui Tang
  • Laleh Amiri-Kordestani

Their work is prominently published in journals such as:

  • Clinical Cancer Research
  • Journal of Clinical Oncology
  • The Oncologist
  • JAMA Oncology
  • Statistics in Biopharmaceutical Research

Best Publications

  • FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

    Bhupinder S. Mann;John R. Johnson;Martin H. Cohen;Robert Justice

  • Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia

    Peter F. Bross;Julie Beitz;Gang Chen;Xiao Hong Chen

  • Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration

    Lilia Talarico;Gang Chen;Richard Pazdur

  • Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

    Robert C. Kane;Peter F. Bross;Ann T. Farrell;Richard Pazdur

  • FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

    Martin H. Cohen;Yuan Li Shen;Patricia Keegan;Richard Pazdur

  • FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

    Martin H. Cohen;Grant A. Williams;Rajeshwari Sridhara;Gang Chen

  • United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets

    Martin H. Cohen;Grant A. Williams;Rajeshwari Sridhara;Gang Chen

  • First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.

    Steven Lemery;Patricia Keegan;Richard Pazdur

  • End Points and United States Food and Drug Administration Approval of Oncology Drugs

    John R. Johnson;Grant Williams;Richard Pazdur

  • Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

    Vicki L. Goodman;Edwin P. Rock;Ramzi Dagher;Roshni P. Ramchandani

  • Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

    Martin H. Cohen;Grant Williams;John R. Johnson;John Duan

  • Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

    Robert C. Kane;Ann T. Farrell;Haleh Saber;Shenghui Tang

  • FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension

    Edvardas Kaminskas;Ann T. Farrell;Yong-Cheng Wang;Rajeshwari Sridhara

  • Approval Summary Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

    Ramzi Dagher;Martin Cohen;Gene Williams;Mark Rothmann

  • Approval summary : azacitidine for treatment of myelodysplastic syndrome subtypes

    Edvardas Kaminskas;Ann Farrell;Sophia Abraham;Amy Baird

  • FDA drug approval summary: erlotinib (Tarceva) tablets.

    Martin H. Cohen;John R. Johnson;Yeh-Fong Chen;Rajeshwari Sridhara

  • FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease†‡§

    Min Lu;Martin H. Cohen;Dwaine Rieves;Richard Pazdur

  • FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

    Dickran Kazandjian;Daniel L. Suzman;Gideon Blumenthal;Sirisha Mushti

  • FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer

    Martin H. Cohen;Joe Gootenberg;Patricia Keegan;Richard Pazdur

  • Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

    Peter F. Bross;Robert Kane;Ann T. Farrell;Sophia Abraham

Frequent Co-Authors

Donna Przepiorka
Donna Przepiorka US Food and Drug Administration
Richard L. Schilsky
Richard L. Schilsky University of Chicago
Mark J. Ratain
Mark J. Ratain University of Chicago
Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Lawrence J. Lesko
Lawrence J. Lesko University of Florida
James L. Abbruzzese
James L. Abbruzzese Duke University
Malcolm A. Smith
Malcolm A. Smith National Institutes of Health
Luc Dirix
Luc Dirix GZA Ziekenhuizen Campus Sint-Augustinus
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Ethan Basch
Ethan Basch University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in medicine can open doors to a wide variety of related degrees and career pathways. Many students choose to start with a cheapest online health science degree as a foundation. These programs are flexible and affordable, helping you build core knowledge in health and science while allowing you to manage other commitments.

For those aiming for leadership roles, the most affordable mha programs (Master of Healthcare Administration) offer advanced training in healthcare management. These online MHA programs are designed for working professionals and can help you move into higher-level positions in hospitals, clinics, or public health organizations.

If you're interested in advanced nursing practice, some of the best online dnp programs (Doctor of Nursing Practice) offer rigorous, evidence-based training for future clinical leaders and nurse practitioners.

Alternatively, for students seeking expertise in pharmacology, there are accredited online pharmacy schools that provide flexible pathways to a Doctor of Pharmacy degree, preparing graduates for rewarding careers in pharmaceutical care and research.

Best Scientists Citing Richard Pazdur

Trending Scientists

Recently Published Articles